entertainment -WSS

entertainment

author：hotspot 2025-08-28 08:40:28 - browse：6965

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Vertex non

Wikipedia

hotspot

WSS

Colonoscopy prep: Liquid

Pancreatic cancer early detection could be helped by AI

Why you shouldn’t ask, “What country has the best health care?”

Pancreatic cancer early detection could be helped by AI

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Methadone treatment changes are coming. Do they go far enough?

leisure time

entertainment

hotspot

How to save PrEP access — and even expand it

Baby aspirin cuts fat buildup in liver disease patients, in small study

As demand for Covid shots wanes, Moderna seeks its next success

Colonoscopy prep: Liquid

How one medical school became remarkably diverse

Venture capital firm's plans to take over Akron hospital face hurdles

Medical leaders decry Supreme Court decision on affirmative action

10 reasons why health care startups fail

Anesthesiologist group: stop taking Ozempic before surgery

Stop the failed accountable care organization experiment

hotspot

Asbestos, a deadly carcinogen, banned by EPA

Readout Newsletter: The latest on Novavax, Merck, Bluebird

10 reasons why health care startups fail

Vertex non

Health AI adoption puts security, privacy startups on investors' radar

How generative AI ratchets up security threats for health systems

knowledge

Wikipedia

hotspot

leisure time